KOL Identification

A global private equity firm wanted to project the revenues and competitive positioning of a leading oncology diagnostics provider to support a growth capital investment

A major diagnostics manufacturer had developed a novel technology for the rapid detection of infectious pathogens and required assistance in developing commercialization strategy and sales tactics. DeciBio’s services were contracted to profile relevant stakeholders, characterize existing workflows and acquisition / implementation processes, and develop a product-specific launch strategy.

A large pharmaceutical company engaged DeciBio to evaluate strategies for an internal build of a lab to support clinical and commercial opportunities in oncology

A large multi-national diagnostic company was interested in understanding the market landscape and potential strategy for the decentralization of NIPT in the U.S.

A diagnostic company wanted to assess the current and expected future landscapes for biopharma oncology genomics research and Dx / CDx

A startup wanted to understand how customers could use its cutting-edge technology and which applications to target for further development